Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01592383 · OUTCOME

PFS

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma · Source last updated 2018-10-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
1 year

What was measured

Progression free survival (PFS) defined as time from study enrollment until disease progression or death.

Analysis population: The study was terminated early after the enrollment of two participants and the data were not collected.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor Therapy)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Progression free survival (PFS) defined as time from study enrollment until disease progression or death.
groups
  1. description
    Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Enzyme Inhibitor Therapy)
population Description
The study was terminated early after the enrollment of two participants and the data were not collected.
reporting Status
POSTED
time Frame
1 year
title
PFS
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice